Empirical Antibiotic Therapy Advice Pathway

⚙ Clinical Scope: Provides evidence-based empirical regimens BEFORE culture results are available, adjusted for Indian ICMR AMRSN resistance data, allergy cross-reactivity, and host risk factors.

1. Clinical Syndrome

Primary System

Specific Condition

2. Host Risk Stratification

Penicillin Allergy Status

MDR Risk Factors (>90 days hospitalisation, recent IV antibiotics, structural lung disease, prior ESBL/CRE/MRSA) Immunocompromised (Active chemotherapy, HIV/AIDS, immunosuppressants, solid organ transplant) Pregnant or Breastfeeding

⚒ ICMR AMRSN Resistance Context

The recommendations in this tool are weighted heavily by data from the Indian Council of Medical Research (ICMR) Antimicrobial Resistance Surveillance Network.

Enterobacteriaceae (E. coli, K. pneumoniae)
Over 70-80% of clinical isolates in Indian tertiary centers are Extended-Spectrum Beta-Lactamase (ESBL) producers. Routine empirical use of 3rd generation cephalosporins (e.g., Ceftriaxone) for healthcare-associated Gram-negative infections is highly discouraged due to unacceptable failure rates.

Carbapenem-Resistant Enterobacteriaceae (CRE)
Driven by NDM and OXA-48-like enzymes, CRE prevalence approaches 30-40% in ICU settings. For septic shock with MDR risk, escalating to Polymyxins (Colistin/Polymyxin B), Ceftazidime-Avibactam + Aztreonam, or high-dose prolonged-infusion Carbapenems is often necessary.

Staphylococcus aureus (MRSA)
MRSA rates hover between 30-45% nationwide. Vancomycin or Teicoplanin remains the backbone for empirical coverage of severe healthcare-associated Gram-positive infections or suspected line-associated bloodstream infections.

💡 Cross-Reactivity & Stewardship

Beta-Lactam Cross-Reactivity Rules Applied

The logic engine strictly enforces the following rules based on the user's input for Penicillin (PCN) allergy:

Mild Allergy: Avoid penicillins. 3rd/4th generation cephalosporins (e.g., Ceftriaxone, Cefepime) and Carbapenems are permitted but flagged with a caution. Cross-reactivity is primarily based on side-chain similarity (e.g., Ampicillin and Cephalexin share side chains).
Severe Allergy (Anaphylaxis/IgE-mediated): Strict avoidance of all Penicillins and Cephalosporins. Aztreonam (a monobactam) lacks cross-reactivity with PCN and is heavily utilized as the Gram-negative backbone in severe allergy pathways, alongside Fluoroquinolones or Aminoglycosides.

De-escalation Principle

Empirical therapy is by nature excessively broad to prevent mortality from "missing" the causative organism. It is a mandatory clinical requirement to de-escalate or narrow therapy at 48-72 hours once blood, urine, or tissue culture susceptibilities result.

Algorithm References & Evidence Base